A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer

Protocol No
HCRN-GU15-215
Principal Investigator
Deepak Kilari
Phase
II
Summary
Most individuals who are not able to have the usual chemotherapy are given a different, generally less effective type of chemotherapy called carboplatin. Recently, atezolizumab, which is a type of immunotherapy, was approved by the FDA for the treatment of some patients in your situation. Immunotherapy works by re-activating your immune system to fight cancer and was shown to work in about 23% of patients with your cancer type, but who could not receive the usual chemotherapy. The purpose of this study is to evaluate any good and bad effects of treating urothelial of cancer with atezolizumab plus bevacizumab. Atezolizumab is already a U.S. Food and Drug Administration (FDA) approved standard treatment for advanced urothelial cancer for some people who cannot safely receive cisplatin chemotherapy, and this study will assess the effect (good or bad) of adding bevacizumab to standard atezolizumab. You will receive atezolizumab plus bevacizumab as the first treatment for your advanced urothelial cancer. Bevacizumab plus atezolizumab has shown safety when combined. The study doctors would like to determine if the combination of atezolizumab and bevacizumab is more effective in controlling your cancer.
Description
The purpose of this study is to evaluate any good and bad effects of treating urothelial of cancer
with atezolizumab plus bevacizumab.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: